重大经营与投资决策管理制度 昆山新莱洁净应用材料股份有限公司 二〇二四年四月 1 昆山新莱洁净应用材料股份有限公司 重大经营与投资决策管理制度 第一章 总则 第一条 为规范昆山新莱洁净应用材料股份有限公司（以下简称"公司"） 的重大经营及投资决策程序，建立系统完善的重大经营及投资决策机制，确保决 策的科学、规范、透明，有效防范各种风险，保障公司和股东的利益，根据有关 法律、法规及《昆山新莱洁净应用材料股份有限公司章程》（以下简称"《公司章 程》"）的规定，制定本制度。 第二条 重大经营与投资决策管理的原则： （一）遵守国家法律、法规，符合国家产业政策； （二）符合公司发展战略及经营规划，突出公司主营业务； （三）严格执行决策程序，科学决策，规范管理，控制风险。 第三条 公司各部门及总经理办公室为公司重大经营决策的职能部门，负责 重大经营事项的承揽、论证、实施和监控；总经理办公室为公司管理投资事项的 职能部门，负责公司投资项目的规划、论证、监控以及年度投资计划的编制和实 施过程的宏观监控。 第二章 决策范围 第四条 依据本制度进行的重大经营及投资事项包括： （一）购买或者出售资产； （二）对外投资（含委托理财、 ...

长江证券承销保荐有限公司 关于昆山新莱洁净应用材料股份有限公司 2023 年度募集资金存放与使用情况的核查意见 长江证券承销保荐有限公司（以下简称"长江保荐"）作为昆山新莱洁净应 用材料股份有限公司（以下简称"新莱应材"、"公司"）首次公开发行股票并在 创业板上市的保荐机构，根据《证券发行上市保荐业务管理办法》、《深圳证券 交易所创业板股票上市规则》、《深圳证券交易所上市公司自律监管指引第 2 号 ——创业板上市公司规范运作》等相关规定的要求，对新莱应材 2023 年度募集 资金存放与使用情况进行了核查，核查情况及意见如下： 一、募集资金基本情况 （一）实际募集资金金额、资金到位情况 经中国证券监督管理委员会《关于核准昆山新莱洁净应用材料股份有限公司 公开发行可转换公司债券的批复》（证监许可[2019]2304 号）核准，公司公开发 行 28,000 万元可转换公司债券，每张面值为 100 元人民币，发行数量 280 万张。 此次公开发行可转换公司债券募集资金总额为人民币 280,000,000.00 元，扣除与 本次发行相关的发行费用 10,715,769.94 元，实际募集资金净额为 269,284,23 ...

昆山新莱洁净应用材料股份有限公司 审计报告及财务报表 （2023 年 1 月 1 日至 2023 年 12 月 31 日止） Da Hua Certified Public Accountants（Special General Partnership） 大华审字[2024] 0011006076 号 大 华 会 计 师 事 务 所 (特 殊 普 通 合 伙 ) 昆山新莱洁净应用材料股份有限公司 审计报告 | | 目 | 录 | 页 次 | | --- | --- | --- | --- | | 一、 | 审计报告 | | 1-6 | | 二、 | 已审财务报表 | | | | | 合并资产负债表 | | 1-2 | | | 合并利润表 | | 3 | | | 合并现金流量表 | | 4 | | | 合并股东权益变动表 | | 5-6 | | | 母公司资产负债表 | | 7-8 | | | 母公司利润表 | | 9 | | | 母公司现金流量表 | | 10 | | | 母公司股东权益变动表 | | 11-12 | | | 财务报表附注 | | 1-101 | 大华会计师事务所（特殊普通合伙） 北京市海淀区 ...

Financial Performance - The company's revenue for 2023 was CNY 2,711,397,722.04, representing a 3.49% increase compared to CNY 2,620,064,139.02 in 2022[23]. - Net profit attributable to shareholders decreased by 31.58% to CNY 235,902,603.23 from CNY 344,790,636.72 in the previous year[23]. - The net profit after deducting non-recurring gains and losses was CNY 228,761,397.47, down 33.57% from CNY 344,345,452.03 in 2022[23]. - Basic and diluted earnings per share fell by 61.84% to CNY 0.58 from CNY 1.52 in the previous year[23]. - Total assets at the end of 2023 reached CNY 4,350,299,415.85, an 18.16% increase from CNY 3,681,595,686.84 in 2022[23]. - Net assets attributable to shareholders increased by 11.45% to CNY 1,779,788,600.99 from CNY 1,596,956,639.23 in 2022[23]. - The company reported a quarterly revenue of CNY 734,814,344.70 in Q4 2023, showing a consistent growth trend throughout the year[25]. - The company experienced a decline in return on equity, which was 13.91% in 2023, down from 24.07% in 2022[23]. - The gross profit margin for the food segment was 21.75%, while the pharmaceutical segment's gross profit margin decreased to 36.73%, down by 6.47% year-on-year[77]. - Operating profit decreased by 34.72% to ¥262,278,041.77, while total profit fell by 33.65% to ¥262,167,873.74[144]. Dividend and Profit Distribution - The company plans to distribute a cash dividend of 0.6 RMB per 10 shares to all shareholders, based on a total of 407,806,752.00 RMB[4]. - The board of directors has approved a profit distribution plan, with no bonus shares to be issued[4]. - The company plans to distribute a cash dividend of RMB 1.60 per 10 shares, totaling RMB 36,249,489.12, which accounts for 10.51% of the net profit attributable to shareholders for the year 2022[186]. - The company will increase its share capital by 8 shares for every 10 shares held, resulting in a total increase of 181,247,445 shares, changing the total share capital to 407,806,752 shares[186]. Market and Industry Outlook - The semiconductor manufacturing equipment sales are projected to reach 100 billion in 2023, a decrease of 6.1% from the record 107.4 billion in 2022[33]. - The global semiconductor industry is expected to grow by over 10% in 2024, with a market size approaching 600 billion[35]. - The biopharmaceutical industry in China saw a revenue decline of 4% in 2023, with total revenue of approximately 29.55 billion[37]. - The import and export value of pharmaceuticals in China was 195.36 billion in 2023, a decrease of 11.1% year-on-year[37]. - The domestic semiconductor materials market is expected to benefit from accelerated domestic substitution and supportive national policies[34]. - The company anticipates a strong rebound in the semiconductor market by 2025, driven by capacity expansion and high demand for advanced technologies[35]. Research and Development - The company’s R&D team has over 20 years of industry experience, focusing on high-purity application materials, and has established the Nano Pure and Advantorr brands to fill the domestic market gap[58]. - Research and development expenses rose by 15.15% to CNY 110.34 million, indicating a focus on innovation and product development[86]. - The company is investing heavily in R&D, with a budget increase of 30%, totaling 300 million yuan for new technology development[136]. - The company is focusing on digital transformation and smart manufacturing to enhance production efficiency and reduce costs[146]. - The company is committed to enhancing its core competitiveness through continuous technological innovation and high-quality product offerings[67]. Strategic Initiatives - The company plans to enhance its product development capabilities and expand its international and domestic customer base in 2023[110]. - The company aims to become a global leader in clean equipment and materials manufacturing, focusing on the semiconductor industry[111]. - The company will continue to pursue mergers and acquisitions to enhance its strategic layout in the food and beverage, biopharmaceutical, and semiconductor industries[120]. - The company is considering strategic acquisitions to enhance its product portfolio, with a budget of 500 million yuan allocated for potential deals[136]. - The company plans to optimize its supply chain using AI, IoT, and RPA to reduce costs and ensure timely production, contributing to revenue growth in 2023[120]. Corporate Governance - The company has implemented a series of measures to enhance corporate governance and improve internal control systems[144][145]. - The company has maintained a sound corporate governance structure and effective operational compliance[189]. - The company’s board of directors and supervisory board operate independently[152]. - The company has a clear governance structure in compliance with relevant regulations[152]. - The company has not reported any incidents of fund occupation by controlling shareholders[152]. Environmental Compliance - The company achieved compliance with environmental regulations, obtaining an environmental assessment approval for the semiconductor equipment core aluminum module expansion project on April 27, 2023[196]. - The company reported no instances of exceeding pollutant discharge standards across various categories, including wastewater and waste gas[197]. - The company has established a robust waste management system, ensuring proper classification and disposal of solid waste[199]. - The company adheres to multiple environmental protection laws and standards, demonstrating commitment to sustainable practices[196]. Employee and Management - The total number of employees at the end of the reporting period was 2,643, with 1,149 in the parent company and 1,494 in major subsidiaries[182]. - The company has updated its compensation management system to ensure talent stability and increased the performance bonus distribution ratio[183]. - The company has a strong management team with diverse backgrounds in finance, production, and sales, enhancing its operational capabilities[164]. - The company has a structured remuneration and performance assessment system in place[169]. - The company is focused on expanding its market presence in the domestic food and biopharmaceutical sectors, with Zhang Yu as the sales director for these areas[165].

Financial Performance - The company's revenue for Q1 2024 was ¥688,810,542.01, representing a 7.84% increase compared to ¥638,721,927.11 in the same period last year[5] - Net profit attributable to shareholders was ¥68,498,767.04, a 27.36% increase from ¥53,781,570.59 year-over-year[5] - The net profit after deducting non-recurring gains and losses was ¥59,632,694.42, up 16.48% from ¥51,193,740.23 in the previous year[5] - Total operating revenue for Q1 2024 reached ¥688,810,542.01, an increase of 7.9% compared to ¥638,721,927.11 in Q1 2023[22] - Net profit for Q1 2024 was ¥68,296,508.45, representing a 27.6% increase from ¥53,536,813.14 in Q1 2023[22] - The company's equity increased to ¥1,837,350,931.58, up from ¥1,787,421,265.19, representing a growth of 2.8%[20] - The company reported a comprehensive income total of ¥66,940,183.50, compared to ¥54,383,364.87 in the prior period, reflecting an increase of approximately 23.2%[44] Cash Flow and Investments - The net cash flow from operating activities decreased by 54.60% to ¥11,517,657.13 from ¥25,367,881.46 in the same quarter last year[5] - The company reported a net cash outflow from investing activities of ¥60,324,251.10, a 40.68% decrease compared to the previous year[13] - Cash outflow from operating activities totaled $859,485,363.39, resulting in a net cash flow from operating activities of $11,517,657.13, down 54.5% from $25,367,881.46[49] - Total cash outflow from investment activities was $60,324,251.10, a decrease from $101,999,961.42 in the previous period, showing a reduction of 40.7%[49] Assets and Liabilities - Total assets at the end of the reporting period were ¥4,514,972,267.78, reflecting a 3.79% increase from ¥4,350,299,415.85 at the end of the previous year[5] - Total liabilities increased to ¥2,677,621,336.20, compared to ¥2,562,878,150.66 in the previous period, reflecting a rise of 4.5%[20] - The total current assets increased to ¥2,886,818,929.23 from ¥2,743,009,293.81, reflecting a growth of approximately 5.3%[40] Shareholder Information - The company has a total of 23,489 common shareholders at the end of the reporting period[15] - The largest shareholder, Li Shuibo, holds 25.06% of the shares, totaling 102,200,850 shares[15] - The second-largest shareholder, Shen Anyun, holds 16.71% of the shares, totaling 68,145,300 shares[15] - The company has approved a plan to use repurchased shares for future employee stock ownership plans or equity incentives[17] Share Repurchase - The company plans to repurchase shares with a total amount not less than RMB 50 million and not exceeding RMB 100 million, with a maximum repurchase price of RMB 43.00 per share[17] - As of March 31, 2024, the company has repurchased 1,400,071 shares, accounting for 0.3433% of the total share capital, with a total payment of RMB 39,959,094.85[17] - The largest transaction price during the repurchase was RMB 33.00 per share, while the lowest was RMB 24.62 per share[17] - If the repurchased shares are not used within 36 months after the completion of the repurchase, they will be legally canceled[17] Research and Development - Research and development expenses increased to ¥27,193,417.08 in Q1 2024, compared to ¥21,633,412.28 in Q1 2023, marking a rise of 25.6%[22] Tax and Other Income - The company reported a decrease in tax expenses to ¥9,461,616.41 in Q1 2024 from ¥5,703,631.04 in Q1 2023, indicating improved tax efficiency[22] - Other income surged by 234.64% to ¥10,886,983.97, primarily due to VAT deductions for advanced manufacturing enterprises[13]

根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司治理准则》 《国有企业、上市公司选聘会计师事务所管理办法》和昆山新莱洁净应用材料股份有 限公司（以下简称"公司"）的《公司章程》《董事会审计委员会工作细则》等规定和 要求，董事会审计委员会本着勤勉尽责的原则，恪尽职守，认真履职。现将董事会审 计委员会对会计师事务所2023年度履职评估及履行监督职责的情况汇报如下： 一、2023年年审会计师事务所基本情况 （一）会计师事务所基本情况 昆山新莱洁净应用材料股份有限公司 董事会审计委员会对会计师事务所2023年度履职情况评估及履 行监督职责情况的报告 三、审计委员会对会计师事务所的监督情况 根据公司《董事会审计委员会工作细则》等有关规定，审计委员会对会计师事务 所履行监督职责的情况如下： 大华会计师事务所（特殊普通合伙）（以下简称 " 大华会计师事务所"）成 立于2012年2月（由大华会计师事务所有限公司转制为特殊普通合伙企业），注册 地址为北京市海淀区西四环中路16号院7号楼1101，首席合伙人为梁春先生，拥有 财政部颁发的会计师事务所执业证书，是我国最早从事证券业务的会计师事务所 以及首批获得 H 股 ...

昆山新莱洁净应用材料股份有限公司 昆山新莱洁净应用材料股份有限公司（以下简称"公司"）董事会根据《上市 公司独立董事管理办法》《深圳证券交易所上市公司自律监管指引第 2 号——创 业板上市公司规范运作》等要求，并结合公司现任独立董事陈丽萍女士、何锋女 士、周丽娟女士出具的《独立董事独立性自查情况表》，对公司独立董事的独立 性情况进行评估并出具如下专项意见：经核查独立董事的任职经历以及相关自查 文件，公司现任独立董事陈丽萍女士、何锋女士、周丽娟女士均未在公司担任独 立董事以外的任何职务，也未在公司主要股东担任任何职务，与公司及公司主要 股东之间不存在利害关系或其他可能妨碍其进行独立客观判断的关系，不存在影 响独立性的情况，符合《上市公司独立董事管理办法》《深圳证券交易所上市公 司自律监管指引第 2 号——创业板上市公司规范运作》等法律法规中关于独立董 事的独立性要求。 董事会关于独立董事独立性情况的专项意见 昆山新莱洁净应用材料股份有限公司董事会 2024 年 4 月 24 日 ...

证券代码：300260 证券简称：新莱应材 公告编号：2024-006 昆山新莱洁净应用材料股份有限公司 关于公司股份回购进展情况的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 1、公司未在下列期间回购股份： （1）自可能对本公司证券及其衍生品种交易价格产生重大影响的重大事项 发生之日或者在决策过程中，至依法披露之日内； 重要内容提示： 昆山新莱洁净应用材料股份有限公司（以下简称"公司"）于2023年8月25日 召开第五届董事会第十六次会议和第五届监事会第十六次会议，审议通过了《关 于回购公司部分股份方案的议案》，同意公司使用自有资金以集中竞价交易的方 式回购公司部分股份，用于员工持股计划或者股权激励。本次用于回购的资金总 额不低于人民币5,000万元（含）且不超过人民币10,000万元（含），回购股份的 价格不超过人民币43元/股（含），具体回购股份的金额以回购实施完成时实际回 购的金额为准。本次回购股份的实施期限为自公司董事会审议通过本次回购方案 之日起12个月内。具体情况详见公司于2023年8月29日披露在巨潮资讯网 （www.cninfo.com.c ...

证券代码：300260 证券简称：新莱应材 公告编号：2024-005 昆山新莱洁净应用材料股份有限公司 关于公司股份回购进展情况的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 托时间段均符合《深圳证券交易所上市公司自律监管指引第9号——回购股份》 及公司回购股份方案的相关规定。 1、公司未在下列期间回购股份： （1）自可能对本公司证券及其衍生品种交易价格产生重大影响的重大事项 发生之日或者在决策过程中，至依法披露之日内； （2）中国证监会和深圳证券交易所规定的其他情形。 重要内容提示： 昆山新莱洁净应用材料股份有限公司（以下简称"公司"）于2023年8月25日 召开第五届董事会第十六次会议和第五届监事会第十六次会议，审议通过了《关 于回购公司部分股份方案的议案》，同意公司使用自有资金以集中竞价交易的方 式回购公司部分股份，用于员工持股计划或者股权激励。本次用于回购的资金总 额不低于人民币5,000万元（含）且不超过人民币10,000万元（含），回购股份的 价格不超过人民币43元/股（含），具体回购股份的金额以回购实施完成时实际回 购的金额为准。本次回购股份 ...

证券代码：300260 证券简称：新莱应材 公告编号：2024-003 昆山新莱洁净应用材料股份有限公司 关于公司股份回购进展情况的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 昆山新莱洁净应用材料股份有限公司（以下简称"公司"）于2023年8月25日 召开第五届董事会第十六次会议和第五届监事会第十六次会议，审议通过了《关 于回购公司部分股份方案的议案》，同意公司使用自有资金以集中竞价交易的方 式回购公司部分股份，用于员工持股计划或者股权激励。本次用于回购的资金总 额不低于人民币5,000万元（含）且不超过人民币10,000万元（含），回购股份的 价格不超过人民币43元/股（含），具体回购股份的金额以回购实施完成时实际回 购的金额为准。本次回购股份的实施期限为自公司董事会审议通过本次回购方案 之日起12个月内。具体情况详见公司于2023年8月29日披露在巨潮资讯网 （www.cninfo.com.cn）的《关于回购公司部分股份方案的公告》（公告编号：2023- 091）及《回购股份报告书》（公告编号：2023-045）。 根据《深圳证券交易所上市公司自律监管 ...